摘要
目的:研究冠心病患者经皮冠状动脉介入(PCI)治疗前后外周血超敏C反应蛋白(hsCRP)、白介素-4(IL-4)、IL-10水平变化。方法:选择我院收治的冠心病患者90例,随机分为常规治疗组(常规药物治疗)和PCI组(在常规药物治疗基础上行PCI治疗),各45例,持续用药10个月,比较两组治疗前后外周血hsCRP、IL-4、IL-10、血髓过氧化物酶(MPO)、中性粒细胞等指标变化,随访1年心脏事件发生情况。结果:治疗后,与常规治疗组比较,PCI组患者外周血hsCRP[(3.17±0.62)mg/L比(1.96±0.21)mg/L]、IL-4[(7.93±1.48)mg/L比(4.86±1.03)mg/L]、IL-10[(8.52±2.11)mg/L比(5.03±1.86)mg/L]、MPO[(7.96±0.61)ng/ml比(5.41±4.03)ng/ml]、中性粒细胞[(0.65±0.07)×10~9/L比(0.42±0.09)×10~9/L]水平明显降低(P均=0.001)。1年内,PCI组不良心血管事件发生率显著低于常规治疗组(P=0.035)。结论:冠心病患者PCI术后炎性因子水平明显降低,且预后较好。
Objective： To study changes of peripheral blood levels of high sensitive C reactive protein （hsCRP）, interleukin （IL） -4 and IL-10 in patients with coronary heart disease （CHD） before and after percutaneous coronary intervention （PCI）. Methods： A total of 90 CHD patients treated in our hospital were selected, randomly and equally divided into rou- tine treatment group （received routine medication） and PCI group （received PCI based on routine medication）, both groups were treated for continuous 10 months. Peripheral blood levels of hsCRP, IL-4, IL-10, myeloperoxidase （MPO） and neu- trophils before and after treatment were compared between two groups, and patients were followed up for one year to ob- serve incidence of cardiac events. Results： Compared with routine treatment group after treatment, there were significant reductions in peripheral blood levels of hsCRP [（3. 17 ± 0. 62） mg/L vs. （1.96 ±0.21） mg/L], IL-4[（7. 93 ± 1.48） mg/L vs. （4.86 ±1.03） mg/L], [L-10 （-（8. 52 ± 2.11） mg/L vs. （5. 03 ± 1.86） mg/L], MPO[（7. 96 ±0. 61） ng/ml vs. （5.41 ±4. 03） ng/ml] and neutrophils [（0.65 ± 0.07） × 109/L vs. （0. 42 ± 0. 09） × 109/L] in PCI group, P = 0. 001. In one year, incidence rate of adverse cardiovascular events of PC! group was significantly lower than that of routine treatment group, P=0. 035. Conclusion.. Levels of inflammatory factors significantly reduce in CHD patients after PCI, the prognosis
作者
殷娟
姬超
尚晓娜
梁红玲
马永宁
YIN Juan;JI Chao;SHANG Xiao-na;LIANG Hong-ling;MA Yong-ning(De-partment of Function,Second People＇s Hospital of Shaanxi Province,Xian,Shaanxi,710005,China Corresponding author： MA Yong-ning,E-mail： 40961477@qq.com)
出处
《心血管康复医学杂志》
CAS
2018年第4期417-420,共4页
Chinese Journal of Cardiovascular Rehabilitation Medicine
